Brief: Pharma Mar: Boryung Pharmaceutical Announces Superior Potent Results For Plitidepsin Against Sars-Cov-2
02/07/2020 08:38
July 2 (Reuters) - Pharma Mar SA PHMR.MC :
* PHARMA MAR'S PARTNER IN SOUTH KOREA BORYUNG PHARMACEUTICAL
ANNOUNCES SUPERIOR POTENT RESULTS FOR PLITIDEPSIN AGAINST
SARS-COV-2
* SAYS BORYUNG PHARMACEUTICAL IS PREPARING CLINICAL TRIALS
WITH
PLITIDEPSIN IN KOREA AIMING TO BEGIN IN Q3 2020
* SAYS PLITIDEPSIN SHOWED HIGHER ANTI-VIRAL ACTIVITY THAN
REMDESIVIR (COVID-19 MEDICATION IN KOREA) AND HIGHER ACTIVITY
THAN REMDESIVIR IN CALU-3 CELL
Source text for Eikon: ID:nCNM3L9qlf
Further company coverage: PHMR.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Boryung
See all newsBrief: Boryung Corp Q1 Operating Profit 20.2 Billion Won, Up 84.7% From Year Earlier
Brief: Boryung Corp Q4 Operating Profit 20 Billion Won, Up 36% From Year Earlier
Brief: Boryung Corp Q2 Operating Profit 25.4 Billion Won, Up 26% From Year Earlier
Brief: Boryung Q1 Operating Profit 11 Billion Won, Down 33% From Year Earlier
Brief: Boryung Corp Q4 Operating Profit 14.6 Billion Won, Down 1.5% From Year Earlier